The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 19, 2019
Filed:
Apr. 27, 2018
Applicant:
Pharmacyclics Llc, Sunnyvale, CA (US);
Inventors:
Lee Honigberg, San Francisco, CA (US);
David J. Loury, Incline Village, NV (US);
Assignee:
Pharmacyclics LLC, Sunnyvale, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/14 (2017.01); A61K 47/20 (2006.01); A61K 47/26 (2006.01); A61K 47/36 (2006.01); A61K 47/38 (2006.01); A61K 9/48 (2006.01); A61K 31/519 (2006.01); A61K 31/195 (2006.01); A61K 31/436 (2006.01); A61K 31/454 (2006.01); A61K 31/475 (2006.01); A61K 31/573 (2006.01); A61K 31/606 (2006.01); A61K 31/675 (2006.01); A61K 31/69 (2006.01); A61K 31/704 (2006.01); A61K 31/7076 (2006.01); A61K 45/06 (2006.01); A61K 31/4184 (2006.01); A61K 31/4745 (2006.01); A61K 31/7032 (2006.01); A61K 39/395 (2006.01); C07D 487/04 (2006.01); A61K 31/337 (2006.01); A61K 31/437 (2006.01); A61K 31/664 (2006.01);
U.S. Cl.
CPC ...
A61K 31/519 (2013.01); A61K 9/007 (2013.01); A61K 9/0014 (2013.01); A61K 9/0031 (2013.01); A61K 9/0048 (2013.01); A61K 9/0056 (2013.01); A61K 9/06 (2013.01); A61K 31/195 (2013.01); A61K 31/337 (2013.01); A61K 31/4184 (2013.01); A61K 31/436 (2013.01); A61K 31/437 (2013.01); A61K 31/454 (2013.01); A61K 31/475 (2013.01); A61K 31/4745 (2013.01); A61K 31/573 (2013.01); A61K 31/606 (2013.01); A61K 31/664 (2013.01); A61K 31/675 (2013.01); A61K 31/69 (2013.01); A61K 31/704 (2013.01); A61K 31/7032 (2013.01); A61K 31/7076 (2013.01); A61K 39/395 (2013.01); A61K 39/3955 (2013.01); A61K 39/39533 (2013.01); A61K 45/06 (2013.01); C07D 487/04 (2013.01);
Abstract
Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.